Arena Pharmaceuticals, Inc. (ARNA)

[FutureBankruptcy]

Analysts set a 12-month price target of $35.5 a share

http://postanalyst.com/2017/07/03/an-inside-look-at-trading-hot-stocks-avid-technology-inc-avid-arena-pharmaceuticals-inc-arna/

Arena Pharmaceuticals, Inc. (ARNA) Consensus Price Target
The company’s consensus rating on Reuter’s scale slipped from 2.43 to 2.25 during a month. Analysts set a 12-month price target of $35.5 a share. The target implies a 110.43% spike from where the shares are currently trading. Also, the current price highlights a discount of 196.38% to analysts’ high consensus price target.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Intraday Trading
The counter witnessed a trading volume of 0.75 million shares versus an average volume of 0.35 million shares during last trading session. Its last month’s stock price volatility remained 7.44% which for the week approaches 7.22%. The lowest price the stock reached in the last trading day was $15.97 and compares with the $11.3 52-week low. The stock recovered 49.29% since its low point and has performed 18.8% year-to-date.